GID BIO completed an FDA compliant, multi-site, randomized, placebo-controlled Phase IIb clinical trial using autologous stromal cells in the treatment of knee osteoarthritis (OA), successfully meeting endpoints and two-year safety results…
Read more via ORTHOWORLD: https://www.orthoworld.com/index.php/publications/orthoflash/gid-bio-completes-trial-of-stromal-cells-to-treat-knee-oa